The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global NASH Therapeutic Drugs Market Research Report 2024
Synopsis
The global NASH Therapeutic Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for NASH Therapeutic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding NASH Therapeutic Drugs.
Report Scope
The NASH Therapeutic Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global NASH Therapeutic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the NASH Therapeutic Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allergan Plc (Tobira)
Bristol Myers Squibb
Galmed Pharmaceuticals
Genfit SA
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.
Zydus Cadila
Segment by Type
Vitamin E and Pioglitazone
Ocaliva
Elafibranor
Selonsertib and Cenicriviroc
Segment by Application
Hospital Pharmacy
Online Provider
Retail Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of NASH Therapeutic Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global NASH Therapeutic Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for NASH Therapeutic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding NASH Therapeutic Drugs.
Report Scope
The NASH Therapeutic Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global NASH Therapeutic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the NASH Therapeutic Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allergan Plc (Tobira)
Bristol Myers Squibb
Galmed Pharmaceuticals
Genfit SA
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.
Zydus Cadila
Segment by Type
Vitamin E and Pioglitazone
Ocaliva
Elafibranor
Selonsertib and Cenicriviroc
Segment by Application
Hospital Pharmacy
Online Provider
Retail Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of NASH Therapeutic Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global NASH Therapeutic Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Vitamin E and Pioglitazone
1.2.3 Ocaliva
1.2.4 Elafibranor
1.2.5 Selonsertib and Cenicriviroc
1.3 Market by Application
1.3.1 Global NASH Therapeutic Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacy
1.3.3 Online Provider
1.3.4 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global NASH Therapeutic Drugs Market Perspective (2019-2030)
2.2 NASH Therapeutic Drugs Growth Trends by Region
2.2.1 Global NASH Therapeutic Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 NASH Therapeutic Drugs Historic Market Size by Region (2019-2024)
2.2.3 NASH Therapeutic Drugs Forecasted Market Size by Region (2025-2030)
2.3 NASH Therapeutic Drugs Market Dynamics
2.3.1 NASH Therapeutic Drugs Industry Trends
2.3.2 NASH Therapeutic Drugs Market Drivers
2.3.3 NASH Therapeutic Drugs Market Challenges
2.3.4 NASH Therapeutic Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top NASH Therapeutic Drugs Players by Revenue
3.1.1 Global Top NASH Therapeutic Drugs Players by Revenue (2019-2024)
3.1.2 Global NASH Therapeutic Drugs Revenue Market Share by Players (2019-2024)
3.2 Global NASH Therapeutic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by NASH Therapeutic Drugs Revenue
3.4 Global NASH Therapeutic Drugs Market Concentration Ratio
3.4.1 Global NASH Therapeutic Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by NASH Therapeutic Drugs Revenue in 2023
3.5 NASH Therapeutic Drugs Key Players Head office and Area Served
3.6 Key Players NASH Therapeutic Drugs Product Solution and Service
3.7 Date of Enter into NASH Therapeutic Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 NASH Therapeutic Drugs Breakdown Data by Type
4.1 Global NASH Therapeutic Drugs Historic Market Size by Type (2019-2024)
4.2 Global NASH Therapeutic Drugs Forecasted Market Size by Type (2025-2030)
5 NASH Therapeutic Drugs Breakdown Data by Application
5.1 Global NASH Therapeutic Drugs Historic Market Size by Application (2019-2024)
5.2 Global NASH Therapeutic Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America NASH Therapeutic Drugs Market Size (2019-2030)
6.2 North America NASH Therapeutic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America NASH Therapeutic Drugs Market Size by Country (2019-2024)
6.4 North America NASH Therapeutic Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe NASH Therapeutic Drugs Market Size (2019-2030)
7.2 Europe NASH Therapeutic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe NASH Therapeutic Drugs Market Size by Country (2019-2024)
7.4 Europe NASH Therapeutic Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific NASH Therapeutic Drugs Market Size (2019-2030)
8.2 Asia-Pacific NASH Therapeutic Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific NASH Therapeutic Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific NASH Therapeutic Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America NASH Therapeutic Drugs Market Size (2019-2030)
9.2 Latin America NASH Therapeutic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America NASH Therapeutic Drugs Market Size by Country (2019-2024)
9.4 Latin America NASH Therapeutic Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa NASH Therapeutic Drugs Market Size (2019-2030)
10.2 Middle East & Africa NASH Therapeutic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa NASH Therapeutic Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa NASH Therapeutic Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Allergan Plc (Tobira)
11.1.1 Allergan Plc (Tobira) Company Detail
11.1.2 Allergan Plc (Tobira) Business Overview
11.1.3 Allergan Plc (Tobira) NASH Therapeutic Drugs Introduction
11.1.4 Allergan Plc (Tobira) Revenue in NASH Therapeutic Drugs Business (2019-2024)
11.1.5 Allergan Plc (Tobira) Recent Development
11.2 Bristol Myers Squibb
11.2.1 Bristol Myers Squibb Company Detail
11.2.2 Bristol Myers Squibb Business Overview
11.2.3 Bristol Myers Squibb NASH Therapeutic Drugs Introduction
11.2.4 Bristol Myers Squibb Revenue in NASH Therapeutic Drugs Business (2019-2024)
11.2.5 Bristol Myers Squibb Recent Development
11.3 Galmed Pharmaceuticals
11.3.1 Galmed Pharmaceuticals Company Detail
11.3.2 Galmed Pharmaceuticals Business Overview
11.3.3 Galmed Pharmaceuticals NASH Therapeutic Drugs Introduction
11.3.4 Galmed Pharmaceuticals Revenue in NASH Therapeutic Drugs Business (2019-2024)
11.3.5 Galmed Pharmaceuticals Recent Development
11.4 Genfit SA
11.4.1 Genfit SA Company Detail
11.4.2 Genfit SA Business Overview
11.4.3 Genfit SA NASH Therapeutic Drugs Introduction
11.4.4 Genfit SA Revenue in NASH Therapeutic Drugs Business (2019-2024)
11.4.5 Genfit SA Recent Development
11.5 Gilead Sciences, Inc.
11.5.1 Gilead Sciences, Inc. Company Detail
11.5.2 Gilead Sciences, Inc. Business Overview
11.5.3 Gilead Sciences, Inc. NASH Therapeutic Drugs Introduction
11.5.4 Gilead Sciences, Inc. Revenue in NASH Therapeutic Drugs Business (2019-2024)
11.5.5 Gilead Sciences, Inc. Recent Development
11.6 Intercept Pharmaceuticals, Inc.
11.6.1 Intercept Pharmaceuticals, Inc. Company Detail
11.6.2 Intercept Pharmaceuticals, Inc. Business Overview
11.6.3 Intercept Pharmaceuticals, Inc. NASH Therapeutic Drugs Introduction
11.6.4 Intercept Pharmaceuticals, Inc. Revenue in NASH Therapeutic Drugs Business (2019-2024)
11.6.5 Intercept Pharmaceuticals, Inc. Recent Development
11.7 Zydus Cadila
11.7.1 Zydus Cadila Company Detail
11.7.2 Zydus Cadila Business Overview
11.7.3 Zydus Cadila NASH Therapeutic Drugs Introduction
11.7.4 Zydus Cadila Revenue in NASH Therapeutic Drugs Business (2019-2024)
11.7.5 Zydus Cadila Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
